Expansion Opportunity CBSET is actively expanding its facilities in multiple locations, including a 110,000-square-foot Waltham lab and a planned New York presence, backed by a growth investment from Arlington Capital Partners. This signals a need for scalable preclinical infrastructure, facility services, and related support to sustain rapid capacity increases.

Preclinical Capacity With a stated goal to roughly triple preclinical capacity and host foreign biotechs entering the U.S., CBSET presents opportunities for contract research services, tech transfer support, remote monitoring, and regulatory advisory partnerships that can help accelerate onboarding and project throughput.

Strategic Investors The equity investment from Arlington Capital Partners indicates a growth runway and potential ongoing funding rounds for expansion, enabling opportunities in capital equipment, lab integration, and scalable service offerings that align with CBSET’s translational research capabilities.

Disease Focus & Tools CBSET specializes in cardiology, endoscopy, surgery, drug and device delivery, safety evaluation, and diagnostic imaging using minimally invasive techniques, suggesting cross-sell potential for instrumentation, imaging analytics, and safety testing platforms suitable for early-stage product developers.

Security & Compliance The tech stack includes security-focused components (Really Simple SSL, HSTS) signaling a priority on data integrity and compliance, presenting sales angles for validated data management, secure collaboration platforms, and regulatory-ready digital solutions for preclinical programs.